David A. Griffith
Pfizer (United States) · 83 works · 3,562 citations · h-index 28
Top works
- SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1
- Sulfonamidoglycosylation of glycals. A route to oligosaccharides with 2-aminohexose subunits
- Total synthesis of allosamidin: an application of the sulfonamidoglycosylation of glycals
- Remarkable regioselectivity in the chemical glycosylation of glycal acceptors: a concise solution to the synthesis of sialyl-Lewis X glycal.
- Azaglycosylation of complex stannyl alkoxides with glycal-derived iodo sulfonamides: a straightforward synthesis of sialyl-Lewis X antigen and other oligosaccharide domains
- A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
- Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
- Synthesis of the Tricyclic Core of Sarain A. Use of Formaldehyde in an Intramolecular Grigg Azomethine Ylide Cyclization
- The Total Synthesis of Allosamidin. Expansions of the Methodology of Azaglycosylation Pursuant to the Total Synthesis of Allosamidin. A Surprising Enantiotopic Sense for a Lipase-Induced Deacetylation
- Application of Glycals to the Synthesis of Oligosaccharides: Convergent Total Syntheses of the Lewis X Trisaccharide Sialyl Lewis X Antigenic Determinant and Higher Congeners
- Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable
- Progress toward the Synthesis of Sarain A
- Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes
- Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition
- New bicyclic cannabinoid receptor-1 (CB1-R) antagonists
- A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification
- Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist
- Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies™
- Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium
- Progress toward the synthesis of sarain A: An unanticipated rearrangement